These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 30715679)

  • 21. Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article.
    Youssry I; Ayad N
    Ann Hematol; 2024 Aug; 103(8):2613-2619. PubMed ID: 37867187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells.
    Park S; Gianotti-Sommer A; Molina-Estevez FJ; Vanuytsel K; Skvir N; Leung A; Rozelle SS; Shaikho EM; Weir I; Jiang Z; Luo HY; Chui DHK; Figueiredo MS; Alsultan A; Al-Ali A; Sebastiani P; Steinberg MH; Mostoslavsky G; Murphy GJ
    Stem Cell Reports; 2017 Apr; 8(4):1076-1085. PubMed ID: 28111279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
    Eckrich MJ; Frangoul H
    Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
    Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
    Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.
    Lattanzi A; Camarena J; Lahiri P; Segal H; Srifa W; Vakulskas CA; Frock RL; Kenrick J; Lee C; Talbott N; Skowronski J; Cromer MK; Charlesworth CT; Bak RO; Mantri S; Bao G; DiGiusto D; Tisdale J; Wright JF; Bhatia N; Roncarolo MG; Dever DP; Porteus MH
    Sci Transl Med; 2021 Jun; 13(598):. PubMed ID: 34135108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for sickle cell disease: An update.
    Demirci S; Uchida N; Tisdale JF
    Cytotherapy; 2018 Jul; 20(7):899-910. PubMed ID: 29859773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
    Dannenmann B; Nasri M; Welte K; Skokowa J
    Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A justice-based argument for including sickle cell disease in CRISPR/Cas9 clinical research.
    Baffoe-Bonnie MS
    Bioethics; 2019 Jul; 33(6):661-668. PubMed ID: 31107563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
    Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
    Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of genome-editing tools to treat sickle cell disease.
    Tasan I; Jain S; Zhao H
    Hum Genet; 2016 Sep; 135(9):1011-28. PubMed ID: 27250347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction.
    Li C; Ding L; Sun CW; Wu LC; Zhou D; Pawlik KM; Khodadadi-Jamayran A; Westin E; Goldman FD; Townes TM
    Sci Rep; 2016 Jul; 6():30422. PubMed ID: 27460639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome Engineering for Stem Cell Transplantation.
    Argani H
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
    Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
    Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
    Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies.
    Drysdale CM; Nassehi T; Gamer J; Yapundich M; Tisdale JF; Uchida N
    Cell Stem Cell; 2021 Feb; 28(2):191-208. PubMed ID: 33545079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
    Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
    Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo HSC prime editing rescues sickle cell disease in a mouse model.
    Li C; Georgakopoulou A; Newby GA; Chen PJ; Everette KA; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
    Blood; 2023 Apr; 141(17):2085-2099. PubMed ID: 36800642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.